MX2012000018A - Hyr1 como objetivo para inmunizacion activa y pasiva contra candida. - Google Patents

Hyr1 como objetivo para inmunizacion activa y pasiva contra candida.

Info

Publication number
MX2012000018A
MX2012000018A MX2012000018A MX2012000018A MX2012000018A MX 2012000018 A MX2012000018 A MX 2012000018A MX 2012000018 A MX2012000018 A MX 2012000018A MX 2012000018 A MX2012000018 A MX 2012000018A MX 2012000018 A MX2012000018 A MX 2012000018A
Authority
MX
Mexico
Prior art keywords
hyr1
target
active
passive immunization
immunization against
Prior art date
Application number
MX2012000018A
Other languages
English (en)
Spanish (es)
Inventor
Yue Fu
Guanpingsheng Luo
Ashraf Ibrahim
Brad J Spellberg
John E Edwards Jr
Original Assignee
Los Angeles Biomed Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Los Angeles Biomed Res Inst filed Critical Los Angeles Biomed Res Inst
Publication of MX2012000018A publication Critical patent/MX2012000018A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
    • C07K14/39—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts
    • C07K14/40—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts from Candida
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0002—Fungal antigens, e.g. Trichophyton, Aspergillus, Candida
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Passenger Equipment (AREA)
MX2012000018A 2009-07-03 2010-07-02 Hyr1 como objetivo para inmunizacion activa y pasiva contra candida. MX2012000018A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22300509P 2009-07-03 2009-07-03
PCT/US2010/040949 WO2011003085A1 (en) 2009-07-03 2010-07-02 Hyr1 as a target for active and passive immunization against candida

Publications (1)

Publication Number Publication Date
MX2012000018A true MX2012000018A (es) 2012-03-29

Family

ID=43411487

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012000018A MX2012000018A (es) 2009-07-03 2010-07-02 Hyr1 como objetivo para inmunizacion activa y pasiva contra candida.

Country Status (15)

Country Link
US (2) US8709446B2 (https=)
EP (1) EP2448959B1 (https=)
JP (2) JP5690822B2 (https=)
KR (1) KR20120085234A (https=)
CN (1) CN102574895B (https=)
AU (2) AU2010266114B2 (https=)
BR (1) BR112012000036A2 (https=)
CA (1) CA2766805A1 (https=)
ES (1) ES2606555T3 (https=)
IL (1) IL217261A0 (https=)
MX (1) MX2012000018A (https=)
NZ (1) NZ597442A (https=)
RU (2) RU2559537C2 (https=)
SG (1) SG177456A1 (https=)
WO (1) WO2011003085A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070077256A1 (en) 1999-11-19 2007-04-05 Los Angeles Biomedical Research Institute Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis and other infectious agents
WO2011003085A1 (en) 2009-07-03 2011-01-06 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Hyr1 as a target for active and passive immunization against candida
GEP201706766B (en) 2011-07-22 2017-10-25 Los Angeles Biomedical Res Center Methods and compositions for vaccinating against staphylococcus aureus
BR112014005773A2 (pt) * 2011-09-14 2019-09-24 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center composições derivadas de hyr1 e métodos of tratamento usando as mesmas
WO2014144024A1 (en) * 2013-03-15 2014-09-18 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Hyr1 compositions and methods for treating fungal and bacterial pathogens
US10130691B2 (en) 2013-03-15 2018-11-20 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Compositions and methods for treating fungal and bacterial pathogens
GB201306588D0 (en) 2013-04-11 2013-05-29 King S College London Peptides and Binding Partners Therefor
EP3426287A4 (en) 2016-03-09 2020-03-11 Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center Methods and kits for use in preventing and treating vulvovaginal candidiasis
CN113508176A (zh) 2019-02-28 2021-10-15 米尼翁大学 用于控制白色念珠菌感染的反义寡聚物
CN110229221B (zh) * 2019-06-27 2022-04-12 上海交通大学医学院附属仁济医院 一种用于检测侵袭性白色念珠菌病的抗原及其用途
US20220354935A1 (en) * 2021-04-21 2022-11-10 Lundquist Institute For Biomedical Innovation At Harbor-Ucla Medical Center Vaccination against fungal epitopes to prevent inflammatory bowel diseases
WO2025248488A1 (en) * 2024-05-29 2025-12-04 Lundquist Institute For Biomedical Innovation At Harbor-Ucla Medical Center Compositions and methods for preventing and treating healthcare-associated candida auris infections with dual antigen vaccine

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995031998A1 (en) 1994-05-23 1995-11-30 The Research & Development Institute, Inc. Candida albicans adhesin as a vaccine
US6747137B1 (en) * 1998-02-13 2004-06-08 Genome Therapeutics Corporation Nucleic acid sequences relating to Candida albicans for diagnostics and therapeutics
US20070077256A1 (en) * 1999-11-19 2007-04-05 Los Angeles Biomedical Research Institute Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis and other infectious agents
US20060083750A1 (en) * 1999-11-19 2006-04-20 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis
US6734344B2 (en) * 1999-12-10 2004-05-11 Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of Agriculture And Agrifood Coniothyrium minitans β-(1,3) exoglucanase gene cbeg 1
US7241613B1 (en) * 2002-06-05 2007-07-10 Oscient Pharmaceuticals Corporation Identification of Candida cell surface proteins and their uses
RU2316595C1 (ru) * 2006-06-16 2008-02-10 Институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук Способ получения антимикробного пептида ареницина
WO2011003085A1 (en) 2009-07-03 2011-01-06 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Hyr1 as a target for active and passive immunization against candida

Also Published As

Publication number Publication date
KR20120085234A (ko) 2012-07-31
EP2448959B1 (en) 2016-09-07
AU2016244238A1 (en) 2016-10-27
EP2448959A4 (en) 2013-01-02
AU2010266114B2 (en) 2016-07-14
RU2012103502A (ru) 2013-08-10
SG177456A1 (en) 2012-02-28
RU2015122387A (ru) 2015-10-27
US8709446B2 (en) 2014-04-29
NZ597442A (en) 2014-01-31
CN102574895B (zh) 2014-06-11
WO2011003085A1 (en) 2011-01-06
IL217261A0 (en) 2012-02-29
JP2015120722A (ja) 2015-07-02
ES2606555T3 (es) 2017-03-24
BR112012000036A2 (pt) 2018-04-03
RU2015122387A3 (https=) 2019-01-28
RU2559537C2 (ru) 2015-08-10
WO2011003085A9 (en) 2011-07-28
CA2766805A1 (en) 2011-01-06
CN102574895A (zh) 2012-07-11
JP5690822B2 (ja) 2015-03-25
JP2012532114A (ja) 2012-12-13
US20140335114A1 (en) 2014-11-13
EP2448959A1 (en) 2012-05-09
AU2010266114A1 (en) 2012-02-02
US20120237534A1 (en) 2012-09-20

Similar Documents

Publication Publication Date Title
MX2012000018A (es) Hyr1 como objetivo para inmunizacion activa y pasiva contra candida.
MY164607A (en) Solid compositions
EP2739243B8 (en) Pelvic implant system
BRPI1014971A2 (pt) sistema de distribuição de implantes.
EP2470086B8 (en) Improved hip fracture nail system
MX2014008008A (es) Composiciones solidas que comprenden un inhibidor del virus de la hepatitis c.
WO2014052836A3 (en) Methods and compositions for treating infection
WO2012106534A3 (en) Hiv integrase inhibitors
PH12013500065A1 (en) Deuterated n-ethyl-n-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof
TW201144301A (en) Processes for preparing linezolid
TW201129938A (en) Personal mapping system
EP2629975A4 (en) Devices, systems, and methods for the fabrication of tissue
WO2009099768A3 (en) Biodegradable coatings for implantable medical devices
AP2011005802A0 (en) Cyclopentadione derived herbicides.
WO2011138040A3 (en) Vaccine against beta-herpesvirus infection and use thereof
EP2649318A4 (en) Discharge vacuum relief valve for safety vacuum release system
HK1203763A1 (en) Compounds and methods for treating candidiasis and aspergillus infections
IT1402993B1 (it) Corpo valvolare per un gruppo di valvole e gruppo di valvole includente tale corpo valvolare.
WO2011069076A3 (en) Sustained release donepezil formulations
FR2966719B1 (fr) Implant glenoidien.
MX383940B (es) Formulación farmacéutica que contiene tocol fosfato.
WO2011160043A3 (en) Pla2g16 as a target for antiviral compounds
WO2010148314A3 (en) Preparation of esomeprazole and its pharmaceutically acceptable salts
WO2012080176A3 (en) Pharmaceutical compositions comprising alisporivir
MX349563B (es) Formulacion farmaceutica de fenofibrato nanonizado.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal